Findings from a recent study support pretreatment screening for heart disease in patients with newly diagnosed, locoregional esophageal cancer.
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
In this study, skeletal muscle mass, as well as subcutaneous and visceral adiposity, were measured using CT imaging performed at baseline at the level of the L3 vertebrae.
Early detection of malnourishment in patients with gastric and esophageal adenocarcinoma identified as a strategy for improving outcomes for these patients.